ARMR Sciences

What ARMR Sciences does

ARMR Sciences Inc. is a clinical-stage biodefense biotechnology company headquartered in New York that develops immunotherapy-based preventive countermeasures against synthetic drug and chemical/biological threats. Its lead product, ARMR-100, is an anti-fentanyl vaccine that has generated the first-ever anti-fentanyl immune response in humans during a Phase 1/2 trial conducted with Leiden University Medical Center in the Netherlands, showing robust antibody production at the lowest dose and a favorable safety profile in 24 patients dosed across three cohorts.

The company's pipeline is built on its proprietary iMMUNOGEN Technology, an organic molecule platform designed to elicit antibodies that bind synthetic drugs and prevent them from crossing the blood-brain barrier, thereby blocking overdose effects. Pipeline assets include ARMR-200 (nitazenes), ARMR-300 (medetomidine), and ARMR-400 (carfentanil for potential military stockpiles), with sublingual and intramuscular formulations in development. Lead programs are dosed at 1-2x per year for 12-18 months of protection and incorporate a dmLT adjuvant developed at Tulane University.

ARMR is pre-revenue and does not currently sell commercial products. Revenue is expected, post-approval, from biopharmaceutical sales to military and first-responder agencies, government defense stockpiling customers, and ultimately opioid use disorder patient populations; an expanded access program is already in place for physician-requested use. The company has been backed by NIDA (over $20M), the Department of War (foundational research), and other strategic/government capital, and completed a strategic investment from SRX Global in June 2026 alongside an up to $30M capital raise launched in August 2025.

Name

ARMR Sciences

Legal name

ARMR Sciences Inc.

Website

https://armrsciences.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

ARMR Sciences is a clinical-stage biotechnology company developing immunotherapy-based vaccines against synthetic drug threats, with lead candidate ARMR-100 targeting fentanyl. It serves military, first responder, and government biodefense agencies through its iMMUNOGEN platform.

Ownership category

akta.pro rank

Product category

Biodefense Vaccines

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)

Keywords

• Fentanyl vaccine development
• Biodefense countermeasures
• Synthetic opioid vaccines
• Preventive biologics
• Immunotherapy biodefense

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Biopharmaceutical Product Sales: Revenue expected from sales of preventive biologic countermeasures following regulatory approval. Products designed for military, first responders, and opioid use disorder patients. Long-term protection (12-18 months per dose) supports recurring revenue potential.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels11 records

Core offering

ARMR Sciences is a clinical-stage biodefense company developing a pipeline of preventive vaccine countermeasures using its iMMUNOGEN Technology platform of organic molecules designed to activate the human immune system to produce antibodies that bind to synthetic drugs and prevent them from entering the brain. The lead candidate ARMR-100 is a fentanyl vaccine that achieved the first-ever anti-fentanyl immune response in humans in a Phase 1/2 clinical trial. Pipeline products target nitazenes (ARMR-200), medetomidine (ARMR-300), and carfentanil (ARMR-400) for military and civilian use.

Product overview

ARMR Sciences is a clinical-stage biodefense company developing a pipeline of preventive vaccine countermeasures using its iMMUNOGEN Technology platform. The core product is ARMR-100, a fentanyl vaccine that has achieved first-ever anti-fentanyl immune response in humans. The pipeline includes ARMR-200 (nitazenes), ARMR-300 (medetomidine), and ARMR-400 (carfentanil), all utilizing the same platform technology to produce antibodies blocking synthetic drugs from entering the brain. The products are designed to provide 12-18 months of preventive protection and are being developed as sublingual tablets and intramuscular formulations.

Differentiator

Problem solved

Functional benefit

Brands

• ARMR-100: Lead product - fentanyl vaccine candidate in Phase 1/2 clinical trials, designed to produce antibodies that bind to synthetic fentanyl molecules and prevent them from entering the brain
• ARMR-200
• ARMR-300
• ARMR-400
• iMMUNOGEN Technology

Products and services

• ARMR-100 Lead vaccine candidate designed to produce antibodies that bind to synthetic fentanyl molecules and prevent them from entering the brain, potentially preventing overdose effects. Achieved first-ever anti-fentanyl immune response in humans in Phase 1/2 clinical trial with a favorable safety profile. Developed for military personnel, first responders, and ultimately opioid use disorder patients.
• ARMR-200 Vaccine candidate in development for protection against nitazenes, a more potent emerging global synthetic opioid threat. Uses the same iMMUNOGEN Technology platform as ARMR-100 to produce antibodies blocking nitazenes from entering the brain.
• ARMR-300 Vaccine candidate in development for defense against medetomidine, an emerging non-opioid threat without a current solution. Uses the same iMMUNOGEN Technology platform to produce protective antibodies.
• ARMR-400 Military countermeasure in development for potential strategic national stockpiles against carfentanil, an ultra-potent emerging synthetic threat. Designed for defense and biodefense stockpile use cases.

Quantifiable outcome

• First-ever anti-fentanyl immune response generated in humans
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Leiden University Medical CentercoreStrategic or Co-development Partner · 31 March 2026Clinical trial site for Phase 1/2 human trial of anti-fentanyl vaccine ARMR-100. The medical center will conduct the planned fentanyl challenge phase where vaccinated participants' breathing responses will be tested when challenged with intravenous fentanyl doses.
• BARDA (Biomedical Advanced Research and Development Authority)minorStrategic or Co-development PartnerPrior collaboration with BARDA on Anthrax vaccine programs at Emergent BioSolutions resulted in successful BLA approval. Shail Shah, VP of Regulatory Affairs, led the BARDA collaboration that contributed to national stockpile and CBRN-type product development for strategic readiness.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Indivior: Leading opioid use disorder treatment company (Sublocade, Suboxone) and owner of Opiant Pharmaceuticals' naloxone portfolio. Directly comparable as a company addressing the opioid crisis through pharmacological intervention, though using opioid agonist therapy rather than vaccine prevention. Represents both a competitor and adjacent stakeholder in the OUD treatment ecosystem.
• Dynavax Technologies: Vaccine adjuvant company with HEPLISAV-B (CpG 1018 adjuvant) approved for hepatitis B. Comparable as a company leveraging proprietary adjuvant technology to enable novel vaccines, similar to ARMR's use of the dmLT adjuvant from Dr. Elizabeth Norton. Both companies build platform value through adjuvant and antigen innovations.
• Bavarian Nordic: Biodefense-focused vaccine company with approved smallpox (JYNNEOS) and Ebola vaccines and significant BARDA/DoD contracting relationships. Directly comparable business model: developing vaccines for biodefense stockpiling against high-consequence threats, leveraging government funding, and pursuing regulatory pathways for preparedness use cases.
• Braeburn: Commercial-stage company developing long-acting buprenorphine formulations (Brixadi) for opioid use disorder. Comparable as a company addressing OUD with extended-duration pharmacological approaches that improve adherence, similar to ARMR's long-acting vaccine strategy. Targets the same prescriber channels (addiction medicine specialists).

Broad incumbents

• Moderna: Major mRNA vaccine platform with proven ability to scale novel vaccines against emerging threats (COVID-19, RSV, flu). Represents a potential competitive threat if mRNA-based synthetic drug vaccines are pursued, and a benchmark for vaccine platform scale-up and commercial execution.
• Novavax: Clinical-stage vaccine developer with proven platform capabilities (Matrix-M adjuvant, nanoparticle vaccines). ARMR's CMO Seth Toback was previously SVP at Novavax, and both companies pursue novel vaccine approaches for unmet needs with adjuvanted platforms. Comparable in stage and platform-based vaccine development approach.
• Emergent BioSolutions: Established biodefense countermeasure developer with BLA-approved products for anthrax, smallpox, and other CBRN threats. Directly comparable to ARMR as a biodefense-focused vaccine company with BARDA contracting experience (Shail Shah's prior BARDA work was at Emergent). Serves as the benchmark for converting biodefense assets into stockpiling revenue.

Emerging players

• BioXcel Therapeutics: Clinical-stage biopharmaceutical company developing neuroscience-focused therapeutics using AI-enabled drug discovery. Comparable as an emerging player using AI-driven approaches for CNS/neurological conditions, and relevant to ARMR's AI-driven synthetic drug threat platform. Both are clinical-stage, AI-enabled biotechs in adjacent therapeutic areas.
• Curevo Vaccines: Clinical-stage vaccine developer where ARMR's VP of Regulatory Affairs Shail Shah previously served as Senior Director. Comparable as an emerging clinical-stage vaccine company pursuing adjuvanted novel vaccines, with similar regulatory and CMC challenges to ARMR's pipeline programs.

Others

• Hikma Pharmaceuticals: Generic pharmaceutical manufacturer with a leading position in naloxone (Kloxxado) for opioid overdose reversal. Relevant as a comparator in the broader opioid crisis response market, and as a potential commercialization/distribution partner for ARMR's biodefense and OUD products given Hikma's hospital channel relationships.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ARMRsciences
• LinkedInlinkedin.com/company/armrsciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARMR Sciences